Obesity & OverweightNCT07241689
Effects of Protein Supplementation on 4 Weeks of Alternate-day Fasting on Fasting Blood Glucose, Resting Blood Pressure, and Body Composition in Young Men
A study testing protein supplement and No supplementation in people with Obesity & Overweight, run by Nanyang Technological University at 1 site in Singapore.
Trial summary
The objectives of this study are to examine the effects of protein supplementation on 4 weeks of alternate-day fasting (ADF) on fasting blood glucose, resting blood pressure, and body composition in young Asian men with unhealthy body mass index ≥ 23 kg/m2. Read more about this study
- Who is it for?
- Ages 21 to 35 years, men only
- Conditions the study is for
- Obesity & Overweight
- What is being tested?
- protein supplement and No supplementation
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 26 participants
- Where
- 1 siteSingapore
- Study dates
- 17 Jan 2018to 23 Mar 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 35 years
- Men only
- No healthy volunteers
- Adult
Who may be able to join
- Male
- 21 to 35 years old
- Do not smoke or use tobacco products (including shisha)
- Have a body mass index (BMI = body mass in kilograms divided by the square of height in metres) of 23 or greater
Who cannot join
- One cannot participate in or will be released from this study if any of the following conditions or situations applies to them:
- Unable to adhere to requirements regarding physical activity and diet as stated in the methods
- Failed an exercise stress test
- Have any health condition(s) that would be made worse by fasting
- Taking long-term prescribed medication(s) for heart, blood (including blood glucose and blood pressure), lung (except controlled asthma), liver, kidney or joint condition(s)
- Taking other long-term prescribed medication (including traditional Chinese Medicine and other alternative medicine) that are known to affect any of the measurements in this study
- Allergic or intolerant to milk and soy (the protein supplement that participant may be required to consume, contains milk proteins and traces of soy lecithin and lactose)
- Have an artificial electrical implant such as a defibrillator or pacemaker
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effects of Protein Supplementation on 4 Weeks of Alternate-Day Fasting on Blood Parameters and Body Composition in Young Men
The objectives of this study are to examine the effects of protein supplementation on 4 weeks of alternate-day fasting (ADF) on fasting blood glucose, resting blood pressure, and body composition in young Asian men with unhealthy body mass index ≥ 23 kg/m2.
To achieve the objective, 40 young men aged 21 to 35 years old will be recruited to participate in this study and complete a 4-week ADF programme. The fasting programme starts at 12 midnight and alternates between fasting and feeding days. Each fasting or feeding day is 24-hour in duration. On fasting days, no food and beverages are allowed except for ad libitum intake of plain water and/or other zero-calorie beverages, and a small meal between 400-600 kcal. In this study, participants would be randomly assigned to either the control or protein supplementation group (20 in each group). The control group will consume a small meal of their choice as long as it is between 400-600 kcal while the protein supplementation group will consume a small meal between 400-600 kcal that will include a protein supplement that would be provided (125 kcal, 25 g protein) and with the remainder of the meal of their choice. For both groups in this study, the small meal is to be consumed during 12 pm to 2 pm for standardisation to ensure consistency in total duration of fasting and feeding. The programme will end after 4 weeks (28 days) of continuous alternate-day fasting.
Read more
Fasting blood glucose, resting blood pressure and heart rate, body mass, height, and body composition will be measured before and after 4-week of ADF. In addition, these measurements, except body composition, will be repeated at the end of each week of ADF.
The research hypothesis are: 1) 4 weeks of ADF will reduce body mass via both fat and muscle loss, and improve health indices as measured by fasting blood glucose and resting blood pressure in young individuals with BMI greater than the desired healthy range, and 2) protein supplementation during fasting days will reduce muscle loss during loss of body mass.
Read the detailed description
Methods Overview Participation in this study requires a total of 4 weeks of alternate-day fasting and 5 laboratory visits (sessions) spread over 5 weeks.
To participate in this study, participants will have to 1) sign the consent form, 2) complete a questionnaire which assesses their health with respect to the inclusion and exclusion criteria to ensure their safety and participation eligibility, 3) complete weekly questionnaire about their physical activity level, 4) complete 5 times of a health screening (measurement of resting blood pressure and heart rate, fasting blood sugar, body mass and height), 5) complete 2 occasions of body composition measurement, 6) complete 4 weeks of alternate-day fasting programme, and 7) complete 4 x 2-day dietary recalls for a total of 8 days of dietary recalls. Participants will also be required to consume a protein supplement on fasting days if assigned to the protein supplementation group.
Participants are required to:
- follow the fasting programme as instructed including the protein supplementation if assigned (details given below),
- abstain from taking medication (including traditional Chinese medicine) not previously declared unless when ill (participants are instructed to inform the investigators immediately if they fall ill during the study), hormones, steroids, and any supplements external to the study, including protein, vitamin and mineral supplements during the entire duration of the study,
- maintain a consistent physical activity level throughout the entire duration of the study,
- abstain from any physical activity except for activities of daily living for at least 48 hours prior to each session,
- abstain from alcohol and caffeine for at least 24 hours prior to each session,
- fast overnight for 10 hours before each session. In consideration of the fasting and to control for diurnal variation, all sessions will take place in the morning, and
- abstain from all food and beverages during each session except for plain water that you may drink as much as you need.
Session 1: Consent, Questionnaires, Health Screening and Body Composition
Procedures involved:
- Read and sign consent form if participating
- Complete Subject Screening Questionnaire (to assess participants' health with respect to the inclusion and exclusion criteria to ensure their safety and participation eligibility)
- Complete Global Physical Activity Questionnaire (GPAQ; to assess participants' physical activity level)
- Answer questions related to health with respect to the inclusion and exclusion criteria
- Have resting blood pressure and heart rate, body mass, and height measured
- Have fasting blood sugar level measured using finger prick sampling
- Undergo a direct segmental multi-frequency bioelectrical impedance analysis (DSM-BIA) to determine body composition
- Collect the weekly supply of protein supplement in the form of a protein powder to be mixed with a beverage of their choice and to be consumed during the fasting days (see below) for participants assigned to the protein supplementation group.
Alternate-Day Fasting for 4 weeks (start within 1 week from session 1)
Procedures involved:
- Programme starts at 12 midnight
- Alternate between fasting and feeding days
- Each fasting or feeding day is 24-hour in duration
- On fasting days: no food and beverages except for ad libitum intake of plain water and/or other zero-calorie beverages, and a small meal between 400-600 kcal. In this study, participants would be randomly (by chance) assigned to either the standard or protein supplementation group. The standard group will consume a small meal of their choice as long as it is between 400-600 kcal while the protein supplementation group will consume a small meal between 400-600 kcal including the protein supplement (125 kcal, 25 g protein) that is provided and with the remainder of the meal of their choice.
- For both groups in this study, this small meal is to be consumed during 12 pm to 2 pm for standardisation to ensure consistency in total duration of fasting and feeding. One must finish the protein supplement during this period of time if assigned to the protein supplementation group.
- On feeding days: ad libitum eating except no alcohol and caffeine for at least 24 hours prior to sessions 2 to 4 if coinciding with the feeding days.
- Programme ends after 4 weeks (28 days) of continuous alternate-day fasting
Sessions 2 to 4: Dietary Recalls, Health Screening and Questionnaire (at the end of each week of alternate-day fasting, ~1 hour for each session)
Procedures involved:
- Complete a 2-day dietary recall on any 2 fasting days for the past week prior to each session
- Have resting blood pressure and heart rate, body mass, and height measured
- Have fasting blood sugar level measured using finger prick sampling
- Complete Global Physical Activity Questionnaire (GPAQ)
- Collect weekly supply of protein supplement if assigned to the protein supplementation group
Session 5: Dietary Recalls, Health Screening, Questionnaire and Body Composition (last session after 4 weeks of alternate-day fasting, ~1.5 hours)
Procedures involved:
- Complete a 2-day dietary recall on any 2 fasting days for the past week prior to the session
- Have resting blood pressure and heart rate, body mass, and height measured
- Have fasting blood sugar level measured using finger prick sampling
- Complete Global Physical Activity Questionnaire (GPAQ)
- Undergo a direct segmental multi-frequency bioelectrical impedance analysis (DSM-BIA) to determine body composition
- Conditions
- Obesity & Overweight
- Being tested
- protein supplement, No supplementation
- Keywords
- overweight, obesity, intermittent fasting, alternate-day fasting, body composition, muscle, fat, blood pressure, blood glucose, protein supplementation, weight loss
- Medical subject headings
- Obesity, Overweight, Intermittent Fasting, Platelet Glycoprotein IV Deficiency, Weight Loss
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
protein supplementDietary supplement
Protein supplement in the form of a whey protein powder containing 25 g of protein and 125 kcal that is provided during the fasting days
No supplementationOther
Standard ADF protocol of a small meal of their choice between 400-600 kcal during fasting days
| Study group | Role | What they receive |
|---|---|---|
| Control | Active comparator | Standard ADF protocol of a small meal of their choice between 400-600 kcal on 12-2pm during fasting days Receives: Other: No supplementation |
| Protein | Experimental | ADF protocol of a small meal between 400-600 kcal including the protein supplement (125 kcal, 25 g protein) that is provided and with the remainder of the meal of their choice on 12-2pm during fasting days Receives: Dietary Supplement: protein supplement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Body mass
Body mass - a component of body composition.
Measured: Start and end of 4-week intervention
Fat mass
A component of body composition. Total amount of fat mass.
Measured: Start and end of 4-week intervention
Fat-free mass
A component of body composition. Total amount of fat-free mass, which is the total body mass excluding fat. It consists of primarily skeletal muscle mass, and also bone mass.
Measured: Start and end of 4-week intervention
Skeletal muscle mass
A component of body composition. Total amount of skeletal muscle mass.
Measured: Start and end of 4-week intervention
Appendicular fat-free mass
A component of body composition. Sum of skeletal muscle mass in the upper and lower limbs.
Measured: Start and end of 4-week intervention
Percentage body fat
A component of body composition. Percentage of body mass that is made up of fat mass.
Measured: Start and end of 4-week intervention
Visceral fat area
A component of body composition. Amount of visceral fat - a measurement of fat around abdominal organs.
Measured: Start and end of 4-week intervention
Body mass index
A component of body composition. Computed from the measured body mass in kilograms divided by the square of height in metres.
Measured: Start and end of 4-week intervention
Fat mass index
A component of body composition. Total fat mass in kilograms divided by square of height in metres.
Measured: Start and end of 4-week intervention
Fat-free mass index
A component of body composition. Total fat-free mass in kilograms divided by square of height in metres.
Measured: Start and end of 4-week intervention
Skeletal muscle mass index
A component of body composition. Total skeletal muscle mass divided by square of height in metres.
Measured: Start and end of 4-week intervention
Appendicular fat-free mass index
A component of body composition. Total appendicular fat-free mass in kilograms divided by square of height in metres.
Measured: Start and end of 4-week intervention
Secondary outcomes (2)
Fasting blood glucose
Fasting blood glucose
Measured: Weekly from start to end of 4-week intervention
Resting blood pressure
Resting blood pressure
Measured: Weekly from start to end of 4-week intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Nov 2025
- Study start17 Jan 2018
- Primary completion23 Mar 2018
- Study completion23 Mar 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obesity & OverweightStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 26 participants (actual)
Sponsor and investigators
- Lead sponsor
- Nanyang Technological University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07241689
- Sponsor's protocol ID
- IRB-2017-08-010
- Status last verified
- Nov 2025
- First submitted
- 13 Nov 2025
- Last updated
- 21 Nov 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: IPD sharing will be available upon request.
Study at a glance
From the registry record, last updated by the sponsor on 21 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Protein Supplementation on 4 Weeks of Alternate-Day Fasting on Blood Parameters and Body Composition in Young Men
- ClinicalTrials.gov ID
- NCT07241689
- Acronym / sponsor ID
- IRB-2017-08-010
- Conditions
- Obesity & Overweight
- Keywords
- overweight, obesity, intermittent fasting, alternate-day fasting, body composition, muscle, fat, blood pressure
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 26 participants (actual)
- Lead sponsor
- Nanyang Technological UniversityUniversity, hospital or other
- Study start
- 17 Jan 2018 (actual)
- Primary completion
- 23 Mar 2018 (actual)
- Study completion
- 23 Mar 2018 (actual)
- First posted
- 21 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objectives of this study are to examine the effects of protein supplementation on 4 weeks of alternate-day fasting (ADF) on fasting blood glucose, resting blood pressure, and body composition in young Asian men with unhealthy body mass index ≥ 23 kg/m2.
To achieve the objective, 40 young men aged 21 to 35 years old will be recruited to participate in this study and complete a 4-week ADF programme. The fasting programme starts at 12 midnight and alternates between fasting and feeding days. Each fasting or feeding day is 24-hour in duration. On fasting days, no food and beverages are allowed except for ad libitum intake of plain water and/or other zero-calorie beverages, and a small meal between 400-600 kcal. In this study, participants would be randomly assigned to either the control or protein supplementation group (20 in each group). The control group will consume a small meal of their choice as long as it is between 400-600 kcal while the protein supplementation group will consume a small meal between 400-600 kcal that will include a protein supplement that would be provided (125 kcal, 25 g protein) and with the remainder of the meal of their choice. For both groups in this study, the small meal is to be consumed during 12 pm to 2 pm for standardisation to ensure consistency in total duration of fasting and feeding. The programme will end after 4 weeks (28 days) of continuous alternate-day fasting.
Fasting blood glucose, resting blood pressure and heart rate, body mass, height, and body composition will be measured before and after 4-week of ADF. In addition, these measurements, except body composition, will be repeated at the end of each week of ADF.
The research hypothesis are: 1) 4 weeks of ADF will reduce body mass via both fat and muscle loss, and improve health indices as measured by fasting blood glucose and resting blood pressure in young individuals with BMI greater than the desired healthy range, and 2) protein supplementation during fasting days will reduce muscle loss during loss of body mass.
Detailed description
Methods Overview Participation in this study requires a total of 4 weeks of alternate-day fasting and 5 laboratory visits (sessions) spread over 5 weeks.
To participate in this study, participants will have to 1) sign the consent form, 2) complete a questionnaire which assesses their health with respect to the inclusion and exclusion criteria to ensure their safety and participation eligibility, 3) complete weekly questionnaire about their physical activity level, 4) complete 5 times of a health screening (measurement of resting blood pressure and heart rate, fasting blood sugar, body mass and height), 5) complete 2 occasions of body composition measurement, 6) complete 4 weeks of alternate-day fasting programme, and 7) complete 4 x 2-day dietary recalls for a total of 8 days of dietary recalls. Participants will also be required to consume a protein supplement on fasting days if assigned to the protein supplementation group.
Participants are required to:
- follow the fasting programme as instructed including the protein supplementation if assigned (details given below),
- abstain from taking medication (including traditional Chinese medicine) not previously declared unless when ill (participants are instructed to inform the investigators immediately if they fall ill during the study), hormones, steroids, and any supplements external to the study, including protein, vitamin and mineral supplements during the entire duration of the study,
- maintain a consistent physical activity level throughout the entire duration of the study,
- abstain from any physical activity except for activities of daily living for at least 48 hours prior to each session,
- abstain from alcohol and caffeine for at least 24 hours prior to each session,
- fast overnight for 10 hours before each session. In consideration of the fasting and to control for diurnal variation, all sessions will take place in the morning, and
- abstain from all food and beverages during each session except for plain water that you may drink as much as you need.
Session 1: Consent, Questionnaires, Health Screening and Body Composition
Procedures involved:
- Read and sign consent form if participating
- Complete Subject Screening Questionnaire (to assess participants' health with respect to the inclusion and exclusion criteria to ensure their safety and participation eligibility)
- Complete Global Physical Activity Questionnaire (GPAQ; to assess participants' physical activity level)
- Answer questions related to health with respect to the inclusion and exclusion criteria
- Have resting blood pressure and heart rate, body mass, and height measured
- Have fasting blood sugar level measured using finger prick sampling
- Undergo a direct segmental multi-frequency bioelectrical impedance analysis (DSM-BIA) to determine body composition
- Collect the weekly supply of protein supplement in the form of a protein powder to be mixed with a beverage of their choice and to be consumed during the fasting days (see below) for participants assigned to the protein supplementation group.
Alternate-Day Fasting for 4 weeks (start within 1 week from session 1)
Procedures involved:
- Programme starts at 12 midnight
- Alternate between fasting and feeding days
- Each fasting or feeding day is 24-hour in duration
- On fasting days: no food and beverages except for ad libitum intake of plain water and/or other zero-calorie beverages, and a small meal between 400-600 kcal. In this study, participants would be randomly (by chance) assigned to either the standard or protein supplementation group. The standard group will consume a small meal of their choice as long as it is between 400-600 kcal while the protein supplementation group will consume a small meal between 400-600 kcal including the protein supplement (125 kcal, 25 g protein) that is provided and with the remainder of the meal of their choice.
- For both groups in this study, this small meal is to be consumed during 12 pm to 2 pm for standardisation to ensure consistency in total duration of fasting and feeding. One must finish the protein supplement during this period of time if assigned to the protein supplementation group.
- On feeding days: ad libitum eating except no alcohol and caffeine for at least 24 hours prior to sessions 2 to 4 if coinciding with the feeding days.
- Programme ends after 4 weeks (28 days) of continuous alternate-day fasting
Sessions 2 to 4: Dietary Recalls, Health Screening and Questionnaire (at the end of each week of alternate-day fasting, ~1 hour for each session)
Procedures involved:
- Complete a 2-day dietary recall on any 2 fasting days for the past week prior to each session
- Have resting blood pressure and heart rate, body mass, and height measured
- Have fasting blood sugar level measured using finger prick sampling
- Complete Global Physical Activity Questionnaire (GPAQ)
- Collect weekly supply of protein supplement if assigned to the protein supplementation group
Session 5: Dietary Recalls, Health Screening, Questionnaire and Body Composition (last session after 4 weeks of alternate-day fasting, ~1.5 hours)
Procedures involved:
- Complete a 2-day dietary recall on any 2 fasting days for the past week prior to the session
- Have resting blood pressure and heart rate, body mass, and height measured
- Have fasting blood sugar level measured using finger prick sampling
- Complete Global Physical Activity Questionnaire (GPAQ)
- Undergo a direct segmental multi-frequency bioelectrical impedance analysis (DSM-BIA) to determine body composition
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control | Active comparator | Other: No supplementationStandard ADF protocol of a small meal of their choice between 400-600 kcal on 12-2pm during fasting days |
| Protein | Experimental | Dietary Supplement: protein supplementADF protocol of a small meal between 400-600 kcal including the protein supplement (125 kcal, 25 g protein) that is provided and with the remainder of the meal of their choice on 12-2pm during fasting days |
Who may qualify
- Ages
- 21 to 35 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Male
- 21 to 35 years old
- Do not smoke or use tobacco products (including shisha)
- Have a body mass index (BMI = body mass in kilograms divided by the square of height in metres) of 23 or greater
Key exclusion criteria (8 listed)
- One cannot participate in or will be released from this study if any of the following conditions or situations applies to them:
- Unable to adhere to requirements regarding physical activity and diet as stated in the methods
- Failed an exercise stress test
- Have any health condition(s) that would be made worse by fasting
- Taking long-term prescribed medication(s) for heart, blood (including blood glucose and blood pressure), lung (except controlled asthma), liver, kidney or joint condition(s)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| protein supplementProtein supplement in the form of a whey protein powder containing 25 g of protein and 125 kcal that is provided during the fasting days | Dietary supplement | Protein |
| No supplementationStandard ADF protocol of a small meal of their choice between 400-600 kcal during fasting days | Other | Control |
Primary outcome
Body mass
Time frame: Start and end of 4-week intervention
Body mass - a component of body composition.
Fat mass
Time frame: Start and end of 4-week intervention
A component of body composition. Total amount of fat mass.
Fat-free mass
Time frame: Start and end of 4-week intervention
A component of body composition. Total amount of fat-free mass, which is the total body mass excluding fat. It consists of primarily skeletal muscle mass, and also bone mass.
Skeletal muscle mass
Time frame: Start and end of 4-week intervention
A component of body composition. Total amount of skeletal muscle mass.
Appendicular fat-free mass
Time frame: Start and end of 4-week intervention
A component of body composition. Sum of skeletal muscle mass in the upper and lower limbs.
Percentage body fat
Time frame: Start and end of 4-week intervention
A component of body composition. Percentage of body mass that is made up of fat mass.
Visceral fat area
Time frame: Start and end of 4-week intervention
A component of body composition. Amount of visceral fat - a measurement of fat around abdominal organs.
Body mass index
Time frame: Start and end of 4-week intervention
A component of body composition. Computed from the measured body mass in kilograms divided by the square of height in metres.
Fat mass index
Time frame: Start and end of 4-week intervention
A component of body composition. Total fat mass in kilograms divided by square of height in metres.
Fat-free mass index
Time frame: Start and end of 4-week intervention
A component of body composition. Total fat-free mass in kilograms divided by square of height in metres.
Skeletal muscle mass index
Time frame: Start and end of 4-week intervention
A component of body composition. Total skeletal muscle mass divided by square of height in metres.
Appendicular fat-free mass index
Time frame: Start and end of 4-week intervention
A component of body composition. Total appendicular fat-free mass in kilograms divided by square of height in metres.
2 secondary outcomes
Fasting blood glucose
Time frame: Weekly from start to end of 4-week intervention
Resting blood pressure
Time frame: Weekly from start to end of 4-week intervention
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Nov 2025.
- Individual participant dataSharing planned: Yes. IPD sharing will be available upon request.
Related trials for Obesity & Overweight
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing protein supplement and No supplementation in people with Obesity & Overweight, run by Nanyang Technological University at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Body mass (time frame: Start and end of 4-week intervention). The study lists 12 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2025.